Evaluation of efficacy and safety of interferon-free “3D” regimen among patients with non-compensated cirrhosis caused by HCV genotype 1b infection by Bogomolov, Pavel O., Macievich, Mariya V., Bueverov, Alexey O., Beznosenko, Valeriy D., Petrachenkova, Mariya Yu, Koblov, Sergey V., Kokina, Kseniya Yu, Voronkova, Natalya V.

Get full text

48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection by Wedemeyer, Heiner, Schöneweis, Katrin, Bogomolov, Pavel O., Chulanov, Vladimir, Stepanova, Tatyana, Viacheslav, Morozov, Allweiss, Lena, Dandri, Maura, Ciesek, Sandra, Dittmer, Ulf, Haefeli, Walter-Emil, Alexandrov, Alexander, Urban, Stephan

Get full text

AS072 - 48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection by Wedemeyer, Heiner, Schöneweis, Katrin, Bogomolov, Pavel O., Chulanov, Vladimir, Stepanova, Tatyana, Viacheslav, Morozov, Allweiss, Lena, Dandri, Maura, Ciesek, Sandra, Dittmer, Ulf, Haefeli, Walter-Emil, Alexandrov, Alexander, Urban, Stephan

Get full text

GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chro... by Wedemeyer, Heiner, Schöneweis, Katrin, Bogomolov, Pavel O., Voronkova, Natalia, Chulanov, Vladimir, Stepanova, Tatyana, Bremer, Birgit, Allweiss, Lena, Dandri, Maura, Burhenne, Jürgen, Haefeli, Walter-Emil, Ciesek, Sandra, Dittmer, Ulf, Alexandrov, Alexander, Urban, Stephan

Get full text

Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial by Wedemeyer, Heiner, Aleman, Soo, Brunetto, Maurizia, Blank, Antje, Andreone, Pietro, Bogomolov, Pavel, Chulanov, Vladimir, Mamonova, Nina, Geyvandova, Natalia, Morozov, Viacheslav, Sagalova, Olga, Stepanova, Tatyana, Berger, Annemarie, Ciesek, Sandra, Manuilov, Dmitry, Mercier, Renee-Claude, Da, Ben L., Chee, Grace M., Li, Mingyang, Flaherty, John F., Lau, Audrey H., Osinusi, Anu, Schulze zur Wiesch, Julian, Cornberg, Markus, Zeuzem, Stefan, Lampertico, Pietro

Get full text

Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study by Wedemeyer, Heiner, Aleman, Soo, Brunetto, Maurizia, Blank, Antje, Andreone, Pietro, Bogomolov, Pavel, Chulanov, Vladimir, Mamonova, Nina, Geyvandova, Natalia, Viacheslav, Morozov, Sagalova, Olga, Stepanova, Tatyana, Manuilov, Dmitry, Mercier, Renee-Claude, An, Qi, Flaherty, John F., Osinusi, Anu, Lau, Audrey, zur Wiesch, Julian Schulze, Cornberg, Markus, Zeuzem, Stefan, Lampertico, Pietro

Get full text

Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic... by Lampertico, Pietro, Aleman, Soo, Blank, Antje, Bogomolov, Pavel, Chulanov, Vladimir, Mamonova, Nina, Viacheslav, Morozov, Sagalova, Olga, Stepanova, Tatyana, Suri, Vithika, Manuilov, Dmitry, Ye, Lei, Flaherty, John F., Osinusi, Anu, Cornberg, Markus, Brunetto, Maurizia, Wedemeyer, Heiner

Get full text

Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase... by Wedemeyer, Heiner, Aleman, Soo, Brunetto, Maurizia, Blank, Antje, Andreone, Pietro, Bogomolov, Pavel, Chulanov, Vladimir, Mamonova, Nina, Geyvandova, Natalia, Viacheslav, Morozov, Sagalova, Olga, Stepanova, Tatyana, Manuilov, Dmitry, Suri, Vithika, An, Qi, Flaherty, John F., Osinusi, Anu, zur Wiesch, Julian Schulze, Cornberg, Markus, Zeuzem, Stefan, Lampertico, Pietro

Get full text